Pooled expertise against deadly pathogens
Thanks to the pooled expertise of the partners, the iCAIR® consortium is in a position to identify completely new active agents against relevant and often deadly pathogens such as Pseudomonas aeruginosa or Aspergillus fumigatus and to develop them to candidate drugs. Furthermore, the scientists of the consortium identify new compounds that are effective against known viral targets such as hemagglutinin-neuraminidase (HN) and neuraminidase (NA). These are highly relevant in the progression of human parainfluenza virus and influenza infections.
In selected lighthouse projects, iCAIR® has established its position as an expert preclinical development platform for new anti-infective drugs.